Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2003-02-04
2008-12-30
Parkin, Jeffrey S. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
Reexamination Certificate
active
07470430
ABSTRACT:
Modified HIV Env, Gag, Pol, or Nef DNA with improved ability to elicit antibody and CTL responses to HIV antigens have been identified as prototype immunogens for the treatment and prevention of HIV infections. Modifications to Env glycoprotein include deletions in the cleavage site, fusogenic domain, and spacing of heptad repeats 1 and 2 and different COOH-terminal deletions. Other modifications entail expression of Gag-Pol and Gag-Pol-Nef as fusion proteins.
REFERENCES:
patent: 0 335 635 (1989-10-01), None
patent: 0 440 207 (1991-08-01), None
patent: 0 449 116 (1991-10-01), None
patent: WO 98 41536 (1998-10-01), None
patent: WO 00 39302 (2000-07-01), None
patent: WO 02/32943 (2002-04-01), None
International Preliminary Examination Report corresponding to International Application No. PCT/US01/25721, filed Aug. 14, 2001.
Advertisment of NIH: “Modifications of HIV Env, Gag and Pol enhance immunogenicity for genetic immunization” Feb. 26, 2001 (http://ott.od.nih.gov/textonly/E-2/5-00.htm).
Andre, S. et al. 1998. Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage.J. Virol. 72:1497-1503.
Binley, J. M. et al. 1998. Analysis of the interaction of antibodies with a conserved enzymatically deglycosylated core of the HIV type 1 envelope glycoprotein 120.AIDS Res. Hum. Retrovir. 14:191-198.
Binley, J. M. et al. 2000. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure.J. Virol. 74:627-643.
Binley, J., and J. P. Moore. 1997. HIV-cell fusion. The viral mousetrap.Nature387:346-348.
Bolognesi, D. P., and T. J. Matthews. 1998. HIV vaccines. Viral envelope fails to deliver?Nature391:638-639.
Borrow, P. et al. 1994. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection.J. Virol. 68:6103-6110.
Broder, C. C. et al. 1994. Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodies.Proc. Natl. Acad. Sci. USA91:11699-11703.
Bures, R. et al. 2000. Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1.AIDS Res. Hum. Retrovir. 16:2019-2035.
Burton, D. R., and D. C. Montefiori. 1997. The antibody response in HIV-1 infection.AIDS11(Suppl. A):S87-S98.
Cao, Y. et al. 1995. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection.N Engl. J. Med. 332:201-208.
Chakrabarti B.K. et al. 2002. Modifications of the Human Immunodeficiency Virus Envelope Glycoprotein Enhance Immunodeficiency for Genetic Immunization.J. Virol. 76:5357-5368.
Chan, D. C. et al. 1997. Core structure of gp41 from the HIV envelope glycoprotein.Cell89:263-273.
Chen, C., and H. Okayama. 1987. High-efficiency transformation of mammalian cells by plasmid DNA.Mol. Cell. Biol. 7:2745-2752.
Collins, J. L. et al. 1981. Tumorigenicity and lysis by natural killers.J. Exp. Med. 153:89-106.
Connor, R. I. et al. 1998. Immunological and virological analysis of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines.J. Virol. 72:1552-1576.
Dale and Betty Bumpers Vaccine research Center (NIH), Laboratory of Virology, Research Summary, Jan. 25, 2001. (http://www.niaid.nih.gov/vrc
abel/htm).
Eckert, D. M. et al. 1999. Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket.Cell99:103-115.
Evans, T. G. et al. 1999, A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers.J. Infect. Dis. 180:290-298.
Ferrari, G. et al. 1997. Replication-defective canarypox (ALVAC) vectors effectively activate anti-human immunodeficiency virus-1 cytotoxic T lymphocytes present in infected patients: implications for antigen-specific immunotherapy.Blood90:2406-2416.
Gallaher, W. R. et al. 1989. A general model for the transmembrane proteins of HIV and other retroviruses.AIDS Res. Hum. Retrovir. 5:431-440.
Gauduin, M. C. et al. 1997. Passive immunization with a human monoclocal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1.Nat. Med. 3:1389-1393.
Gorse, G. J. et al. 1999. Vaccine-induced cytotoxic T lymphocytes against human immunodeficiency virus type 1 using two complementary in vitro stimulation strategies.Vaccine18:835-849.
Graham, F. L., and A. J. van der Eb. 1973. A new technique for the assay of infectivity of human adenovirus 5 DNA.Virology52:456-467.
Haynes, B. F. 1996. HIV vaccines: where we are and where we are going.Lancet348:933-937.
Hosmalin, A. et al. 1990. An epitope in human immunodeficiency virus 1 reverse transcriptase recognized by both mouse and human cytotoxic T lymphocytes.PNAS USA87:2344-2348.
Huang Y. et al. 2001. Human Immunodeficiency Virus Type 1-Specific Immunity after Genetic Immunization is Enhanced by Modification of Gag and Pol Expression.J. Virol. 75:4947-4951.
Hung, M., P. Patel, S. Davis, and S. R. Green. 1998. Importance of ribosomal frameshifting for human immunodeficiency virus type 1 particle assembly and replication.J. Virol. 72:4819-4824.
Irwin, M. J. et al. 1994. Direct injection of a recombinant retroviral vector induces human immunodeficiency virus-specific immune responses in mice and nonhuman primates.J. Virol. 68:5036-5044.
Jacks T. et al. 1988 Characterization of ribosomal frameshifting in HIV-I gag-pol expression. Nature 331:280-283.
Jin X. et al. 1999. Dramatic rise in plasma viremia after CD8+ T cell depletion in simian immunodeficiency virus-infected macaques.J. Exp. Med. 189:991-998.
Karacostas, V. et al. 1993. Overexpression of the HIV-1 gag-pol polyprotein results in intracellular activation of HIV-1 protease and inhibition of assembly and budding of virus-like particles.Virology193:661-671.
Karlsson, G. B. et al. 1998. The envelope glycoprotein ectodomains determine the efficiency of CD4+ T lymphocyte depletion in simian-human immunodeficiency virus-infected macaques.J. Exp. Med. 188:1159-1171.
Kent, K. A., and J. Robinson. 1996. Antigenic determinants on HIV-1 envelope glycoproteins: a dickens of a time with oligomer twist.AIDS10(Suppl. A):S107-S114.
Klein, R. M. et al. 1995. Kinetics of gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics.J. Exp. Med. 181:1365-1372.
Kotsopoulou E. et al. 2000 A Rev-dependent Human Immunodeficiency Virus type 1 (HIV-1)-based vector that exploits a codon-optimized HIV-1 gag-pol gene.J. Virol. 74:4839-4852.
Koup, R. A. et al. 1994. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.J. Virol. 68:4650-4655.
LaCasse, R. A. et al. 1999. Fusion-competent vaccines: broad neutralization of primary isolates of HIV.Science283:357-362.
Loeb, D. D. et al. 1989. Complete mutagenesis of the HIV-1 protease.Nature340:397-400.
Lu, M., and P. S. Kim. 1997. A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein.J. Biomol. Struct. Dyn. 15:465-471.
Lu, S. et al. 1995. Use of DNAs expressing HIV-1 Env and noninfectious HIV-1 particles to raise antibody responses in mice.Virology209:147-154.
Mangasarian A. et al. 1999 Nef-induced CD4 and Major Histocompatibility Complex class I (MHC-1) down-regulation are governed by distinct determinants: N-terminal alpha helix and proline repeat of Nef selectively regulate MHC-1 trafficking.J. Virol. 73:1964-1973.
Manz, R. et al. 1995, Analysis and sorting of live cells according to selected molecules, relocated to
Chakrabarti Bimal K.
Huang Yue
Nabel Gary J.
Knobbe Martens Olson & Bear LLP
Parkin Jeffrey S.
The United States of America as represented by the Department of
LandOfFree
Modifications of HIV, ENV, GAG, and POL enhance... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modifications of HIV, ENV, GAG, and POL enhance..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modifications of HIV, ENV, GAG, and POL enhance... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4024618